Across TCGA pan-cancer cohorts, FSD2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FSD2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher FSD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FSD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

CESC, UCEC, and GBM are the cancer types where FSD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.144	0.705	.004	18	view →
UCEC	DFS	Median	II,III,IV	0.928	0.436	.020	18	view →
GBM	DFS	Median	All	1.000	0.191	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: FSD2 tumor-vs-normal RNA expression · all FSD2 data types